CUT STACK (150 MG/ML – 10 ML)

Description

Cut Stack

Strength: 150 mg/ml.
Molecular Formula: C17H19N5
Molecular Weight: 322.1023 g/mol
Active Ingredients: Trenbolone Acetate 50 mg, Testosterone Propionate 50 mg,
Drostanolone Propionate 50 mg
CAS number: 434-22-0
Dosage Form: Injectable, oil base sterile solution
Route: Injection
Market Status: Prescription
Company: Hilma Biocare

DESCRIPTION

Cut Stack is an injectable steroid that contains ob is testosterone propionate, trenbolone
acetate and drostanolone propionate. Testosterone propionate is designed to reach peak
testosterone serum levels within 24 hours of IM administration and remain elevated for 2 to 3
days. Testosterone propionate is suitable for the treatment of hypogonadism and other
disorders related to androgen deficiency. Testosterone Propionate has both anabolic and
androgenic effects. Testosterone supplementation has been demonstrated to increase
strength and growth of new muscle tissue, frequently with increases in libido. Trenbolone
Acetate is an anabolic steroid with significant anabolic and androgenic effects. The fast oto
acting ester produces a rapid increase in serum trenbolone levels which remain elevated for
several days thereafter. inon Trenbolone promotes significant increases in strength, muscle
anabolism, appetite, and aggression; and has been demonstrated to reduce body fat.
Drostanolone Propionate is a synthetic derivative of dihydrotestosterone, producing an
anabolic effect and promoting protein synthesis as well as creating positive nitrogen balance
in humans. Since it is a derivative of dihydro- testosterone, drostanolone does not aromatize
to estrogens. Drostanolone Propionate have significant anabolic and androgenic properties
promoting an increase in strength and growth of muscle tissue while acting as an estrogen
antagonist. The combination of a short-acting propionate ester with a long- acting enanthate
ester produces rapid increases in serum drostanolone levels with a sustained duration of 5-
8 days.

ADVERSE REACTIONS

Male: Gynecomastia, s excessive frequency and duration of penile erections, oligospermia.
Skin and Appendages: Hirsutism, male pattern baldness and acne, gynecomastia.
Fluid/electrolyte Disturbances:Retention of sodium, chloride, water, potassium, calcium, and
inorganic phosphates.

Gastrointestinal: Nausea, cholestatic jaundice, alterations in liver function tests; rarely,
hepatocellular neoplasms, peliosis hepatitis, hepatic adenomas, and cholestatic hepatitis.
Hematologic: Suppression of clotting factors II, V, VII, & X; bleeding in patients on anticoagulant therapy.

Nervous System: Increased or decreased libido, head- ache, anxiety, depression, and
generalized paresthesia.

Other: Serum lipid changes, hypercalcaemia, hypertension, oedema, priapism, and
potentiation of sleep apnea.

CONTRAINDICATIONS

Patients with known hypersensitivity to any ingredients in this product. Patients with known
or suspected carcinomas of the breast, testis, or prostate. Patients with severe heart
disease, liver disease of kidney disease or with a history of epilepsy. Products containing
testosterone should not be used in women as they may cause virilization and fetal harm.

PRECAUTIONS

Because androgens may alter serum cholesterol concentra- tion, caution should be used
when administering these drugs to patients with a history of myocardial infarction or coronary
artery disease. Patients on oral anticoagulant therapy require close monitoring especially
when androgens are started or stopped.

Diabetics: androgens may alter the metabolism of oral hypoglycemic agents or may change
insulin sensitivity in patients with diabetes mellitus which may require adjustment of dosage
of insulin and other hypoglycemic drugs.

PATIENT MONITORING

Serum Cholesterol, HDL, LDL, TG. Hemoglobin and Hematocrit, Hepatic function tests –
AST/ALT Prostatic specific antigen- PSA, Testosterone: total, free. and bioavailable.
Dihydrotestosterone & Estradiol Male patients over 40 should undergo a digital rectal
examination and evaluate PSA prior to androgen use. Periodic evaluations of the prostate
should continue while on androgen therapy, especially in patients with difficulty in urination
or with changes in voiding habits.

DOSAGE AND ADMINISTRATION

Daily dosage for males is from 150-450 mg. The drug is not recommended for women.

PRESENTATION

Cut Stack 150 mg/ml, 10 ml multiple dose vial.

STORAGE Store in a cool dry place between 15 – 25°C. Protect from light.